Mostrar el registro sencillo del ítem

dc.contributor.authorGarcia-Broncano, Pilar 
dc.contributor.authorMedrano, Luz Maria 
dc.contributor.authorBerenguer, Juan
dc.contributor.authorGonzález-García, Juan
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorCarrero, Ana
dc.contributor.authorHontañón, Victor
dc.contributor.authorGuardiola, Josep M
dc.contributor.authorCrespo, Manuel
dc.contributor.authorQuereda, Carmen
dc.contributor.authorSanz, José
dc.contributor.authorGarcia-Gomez, Ana Belen 
dc.contributor.authorJimenez, Jose Luis
dc.contributor.authorResino, Salvador 
dc.date.accessioned2020-04-17T09:21:17Z
dc.date.available2020-04-17T09:21:17Z
dc.date.issued2018-11-02
dc.identifier.citationCells. 2018 Nov 2;7(11). pii: E196.es_ES
dc.identifier.issn2073-4409es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/9594
dc.description.abstractBACKGROUND: Advanced cirrhosis is related to alterations in immunity. We aimed to evaluate the levels of peripheral CD4⁺ T cells (Tregs) and plasma cytokine in patients coinfected with human immunodeficiency virus and hepatitis C virus (HIV/HCV) according to liver fibrosis stages [evaluated as liver stiffness measure (LSM)] and their linear relationship. METHODS: We performed a cross-sectional study on 238 HIV/HCV-coinfected patients (119 had <12.5 kPa, 73 had 12.5⁻25 kPa, and 46 had >25 kPa). Peripheral T-cell subsets were phenotyped by flow cytometry, plasma biomarkers were assessed by multiplex immunoassays, and LSM was assessed by transient elastography. Results: We found HIV/HCV-coinfected patients had higher values of CD4⁺ Tregs (p < 0.001), memory Tregs (p ≤ 0.001), and plasma cytokine levels [IFN-γ (p ≤ 0.05) and IL-10 (p ≤ 0.01)] compared with healthy donors and HIV-monoinfected patients. In the multivariate analysis, higher LSM values were associated with reduced levels of IL-10 (adjusted arithmetic mean ratio (aAMR) = 0.83; p = 0.019), IL-2 (aAMR = 0.78; p = 0.017), TNF-α (aAMR = 0.67; p < 0.001), and IL-17A (aAMR = 0.75; p = 0.006). When we focus on HIV/HCV-coinfected patients analyzed by LSM strata, patients with ≥25 kPa had lower values of IL-2 (aAMR = 0.66; p = 0.021), TNF-α (aAMR = 0.565; p = 0.003), and IL-17A (aAMR = 0.58; p = 0.003) than patients with <12.5 kPa. CONCLUSION: HIV/HCV-coinfected patients showed an immunosuppressive profile compared to healthy controls and HIV-monoinfected patients. Additionally, HIV/HCV-coinfected patients with advanced cirrhosis (LSM ≥ 25 kPa) had the lowest plasma values of cytokines related to Th1 (IL-2 and TNF-α) and Th17 (IL-17A) response.es_ES
dc.description.sponsorshipThis study was supported by grants from Instituto de Salud Carlos III (ISCII; grant numbers grant numbers PI14/01094 and PI17/00657 to JB, PI14/01581 and PI17/00903 to JGG, PI14CIII/00011 and PI17CIII/00003 to SR, and PI17/01115 to JLJ), Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11-241), Comunidad de Madrid (B2017/BMD3703). The study was also funded by the RD16CIII/0002/0002, RD16/0025/0018, and RD16/0025/0017 projects as part of the Plan Nacional R + D + I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER). J.B. is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT15/00079 and INT16/00100.es_ES
dc.language.isoenges_ES
dc.publisherMultidisciplinary Digital Publishing Institute (MDPI) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHIVes_ES
dc.subjectTreg cellses_ES
dc.subjectChronic hepatitis Ces_ES
dc.subjectCirrhosises_ES
dc.subjectCytokineses_ES
dc.subjectImmune dysfunctiones_ES
dc.titleDysregulation of the Immune System in HIV/HCV-Coinfected Patients According to Liver Stiffness Statuses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID30400258es_ES
dc.format.volume7es_ES
dc.format.number11es_ES
dc.format.page196es_ES
dc.identifier.doi10.3390/cells7110196es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderMinisterio de Sanidad, Servicios Sociales e Igualdad (España) 
dc.contributor.funderComunidad de Madrid (España) 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/cells7110196es_ES
dc.identifier.journalCellses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14/01094es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17/00657es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14/01581es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17/00903es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI14CIII/00011es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17CIII/00003es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/PI17/01115es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/EC11-241es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/B2017/BMD3703es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16/0025/0018es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/RD16/0025/0017es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/INT15/00079es_ES
dc.relation.projectIDinfo:eu_repo/grantAgreement/ES/INT16/00100es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución 4.0 Internacional